Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy by unknown
Xing et al. BMC Immunology  (2015) 16:39 
DOI 10.1186/s12865-015-0103-2RESEARCH ARTICLE Open AccessDexamethasone enhances programmed cell
death 1 (PD-1) expression during T cell activation:
an insight into the optimum application of
glucocorticoids in anti-cancer therapy
Kailin Xing1,2, Bingxin Gu2,3, Ping Zhang4 and Xianghua Wu1,2*Abstract
Background: Programmed cell death 1 (PD-1) is a key cell-surface receptor of CD28 superfamily that triggers inhibitory
pathways to attenuate T-cell responses and promote T-cell tolerance. As a crucial role in tumor immunity, PD-1
has been a focus of studies in anti-cancer therapy. It has been approved that tumors could exploit PD-1-dependent
immune suppression for immune evasion. Considering the wide use of glucocorticoids (GCs) in anti-cancer therapy
and their immunosuppressive effects, we explored whether GCs could influence the expression of PD-1.
Results: In our study, we used dexamethasone (DEX) as a model glucocorticoid and demonstrated that DEX could
enhance PD-1 expression in a dose-dependent manner. The effects were completely inhibited by the glucocorticoid
receptor (GR) antagonist mifepristone (RU486), indicating that the effect of DEX on PD-1 is mediated through GR. We
further found the sensitivity to DEX-induced upregulation of PD-1 expression had a significant difference between
different T cell subsets, with memory T cells more susceptible to this effect. We also showed that DEX could suppress
T cell functions via inhibition of cytokines production such as IL-2, IFN-γ, TNF-α and induction of apoptosis of T cells.
Conclusion: Our findings suggest a novel way by which DEX suppress the function of activated T lymphocytes by
enhancing expression of PD-1 and provide an insight into the optimum clinical application of GCs.
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Glucocorticoids (GCs) have been widely used as im-
munosuppressive and anti-inflammatory agents in the
treatment of numerous autoimmune and inflammatory
diseases. They also play an important role in anti-cancer
therapy. The potent capacity to kill lymphoid cells has
led to their inclusion in all chemotherapy protocols for
lymphoid malignancies [1], e.g., prednisone combined
with rituximab, cyclophosphamide, doxorubicin and vin-
cristine (R-CHOP) acts as the standard first-line therapy
for diffuse large B-cell lymphoma (DLBCL). Besides, GCs
are widely used as co-medication in cancer therapy of* Correspondence: xhwu2015@yahoo.com
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hypersensitivity reactions and other adverse effects such as
nausea, emesis and toxic reactions [2, 3]. Before, during
and after chemotherapy of solid malignant tumors, GCs
are given at varying doses to reduce acute toxicity or to
protect normal tissue [4].
However, accumulating evidences show that the applica-
tion of GCs may interfere with the therapeutic efficacy in
anti-cancer therapy. It renders the majority of malignant
tumor cells resistant to apoptosis and promotes prolifera-
tion in several established and primary carcinoma cancer
cells [5, 6]. Dexamethasone (DEX), an important member
of glucocorticoid family, has been approved to antagonize
the efficacy of some anti-cancer drugs such as cisplatin,
5-fluorouracil, actinomycin D, doxorubicin and gemcitabine
[7, 8]. In addition, M. Xia found that DEX could enhancele distributed under the terms of the Creative Commons Attribution License
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gen (CTLA)-4 during T cell activation [9], indicating that
DEX might suppress antitumor immune responses and
facilitate tumor progression.
Similar to CTLA-4, programmed cell death 1 (PD-1) is
a key cell-surface receptor of CD28 superfamily that
triggers inhibitory pathways and dampens T-cell activity
when bound by its ligands, PD-L1 or PD-L2 [10]. Studies
have shown that PD-1 is highly expressed on tumor infil-
trating lymphocytes and PD-L1 is commonly up-regulated
on many different tumor types, resulting in the inhibition
of local anti-tumor T cell responses [11]. Cancers can
elude immune surveillance through PD-1/PD-L1 pathway
and pre-clinical studies demonstrated that high levels of
expression of PD-L1 correlates with poor prognosis of
cancer [12–14]. However, it still remains unclear how the
expression of PD-1 and its ligands are spatially and tem-
porally regulated and what are the molecular mechanisms
of signaling through PD-1 and its ligands. Based on the
evidence that DEX could enhance CTLA-4 expression [9],
we explored whether DEX could enhance PD-1 expression
as well. Our results demonstrated that DEX could also en-
hance the expression of PD-1 both in mouse and human




Female Balb/c mice of 6–8 weeks of age were purchased
from Ling Chang Corporation (Shanghai, China). All mice
were kept under specific pathogen-free conditions in the
Experimental Animal Center of Fudan University. All of
the experiments were approved by the Institutional
Animal Care and Use Committee of Fudan University.
Mouse T-cell isolation and sorting
Mouse lymphocytes were harvested from spleens of Balb/c
mice by grinding tissue through sterile wire mesh. T cells
were purified by the Pan T Cell Isolation Kit by using
EasySep beads (STEMCELL Technologies Inc., Canada)
following manufacturer's instructions. Postsorting analysis
of purified subsets revealed greater than 95 % purity.
Human T-cell isolation and sorting
Peripheral blood mononuclear cells (PBMCs) were har-
vested from healthy donors after informed consent. This
study has been approved by the Ethics Committee of
Fudan University Shanghai Cancer Center. PBMCs were
isolated by Ficoll-Paque PLUS (GE Healthcare), and
enriched for CD3+ cells with the Pan T Cell Isolation
Kit by using EasySep beads (STEMCELL Technologies
Inc., Canada) following the manufacturer’s instructions.
Postsorting analysis of purified subsets revealed greater
than 95 % purity.Cell culture and treatment
Sorted T cells were resuspended in RPMI1640 medium
containing 10 % heat inactivated fetal bovine serum and
2 mM L-glutamine (Gibco). Cells were cultured in 24-
well plates and stimulated with anti-CD3/CD28 coated
beads following manufacturer’s instructions. Beads were
removed before flow cytometry. DEX (10−9–10−5 M),
RU486 (10−9–10−5 M) were added as treatment groups.
The media (with fresh DEX or RU486 as appropriate)
were changed every 3 days. Cells were incubated at 37 °C
in 5 % CO2 before being collected and analyzed by flow
cytometry.
Reagents
DEX was purchased from Sigma. Hydrocortisone was
from Tianjin Biochem Pharmaceutical Cooperation
(China), Mifepristone (RU486) was from Tokoyo Chem-
ical Industry (TCI, Japan). Antibodies for flow cytometry,
including Percp-cy5.5 labeled anti-mouse or human
CD3, Alexa Fluor 700 labeled anti-mouse or human
CD4, APC labeled anti-mouse or human CD8, FITC
labeled anti-mouse CD44, PE labeled anti-mouse CD62L,
APC or PE labeled anti-mouse or human PD-1 and PD-1
isotype were all purchased from Biolegend. Mouse or
human T-activator CD3/CD28 beads were obtained
from Gibco (Invitrogen Life Technologies). Mouse or
human Pan T Cell Isolation Kit were from STEMCELL
Technologies Inc.
Flow cytometry analysis
Cultured T cells were collected at indicated time after
stimulated by anti-CD3/CD28 beads at 1:1 bead-to-cell
ratio and analyzed by flow cytometry. Cells were washed
with PBS twice and incubated for 20 min at room
temperature in cell staining buffer (Biolegend) with differ-
ent combinations of the surface staining antibodies. After
washing with PBS twice, the stained cells were analyzed
on Beckman Counter FC500. All data were analyzed with
FlowJo software (Tree Star, Inc.).
Quantitative Real-time PCR
Sorted mouse T cells were activated and treated with or
without DEX (1 × 10−7 M). RNA was extracted after
48 h of the treatment using Trizol Reagent (Invitrogen)
and subjected to reverse transcription using PrimeScript
RT reagent Kit (Takara Bio Inc., Japan). After quantified
by spectrophotometry, Real-time (RT)-PCR amplification
was performed with a Mastercycler® pro (Eppendorf,
Hamburg, Germany) using SYBR Green (Takara Bio Inc.,
Japan) under the following conditions: 95 °C for 30 s
followed by 40 cycles of 95 °C for 5 s, 62 °C for 34 s and a
melting curve collection. The primer sets used for amplifi-
cation were: PD-1-F: 5'-TGCTCAACAAGTATGTCAGAG
G-3'; PD-1-R: 5'-ACACTAGGGACAGGTGCTGC-3';
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R: 5'-CAATAGTGATGACCTGGCCGT-3'. β-actin was
used in parallel reactions as internal control. Statistical
analyses were performed using the 2-ΔCT relative quantifi-
cation method.
Western blot analysis
Sorted mouse T cells were activated and treated with or
without DEX (1 × 10−7 M). After 48 h, cells were collected
and lysed in RIPA buffer supplemented with complete
protease inhibitor cocktail (Roche, Basel, Switzerland).
Protein concentrations were determined using the BCA
protein assay kit (Biyotime, Shanghai, China). Cell lysates
(20 μg) were separated by SDS-PAGE and transferred into
polyvinylidene fluoride (PVDF). The membrane was then
blocked with 5 % skim milk in PBST (0.29 % Na2HPO4,
0.8 % NaCl, 0.02 % KCl, and 0.05 % Tween-20, pH7.4) for
2 h at room temperature and then incubated with anti-
PD-1 mAb (Abcam) at 4°Covernight. After washing three
times with PBST, the membrane was incubated with HRP-
conjugated secondary antibody (Immunology Consultants
Laboratory, Inc.) and detected by enhanced chemilumin-
escence reagent (Pierce, Rockford, IL, USA). Anti-β-actin
mAb (Cell Signaling Technology, USA) was used as in-
ternal standard.
ELISAs for cytokine production
The culture supernatants of mouse activated T cells were
removed 48 h after different treatments and kept at −80 °C
until cytokine measurement. IL-2, TNF-α and IFR-γ
productions were measured using quantitive immuno-
assay ELISA kits (R&D Systems, Minneapolis, MN, USA)
in 96-well microtiter plates according to the manufac-
turer’s instructions. The concentration of the cytokines
in each sample was obtained by extrapolation from a
standard calibration curve generated simultaneously. Re-
sults were expressed as pg/mL.
Analysis of apoptosis
Mouse activated T cells were cultured in the absence or
presence of DEX (1 × 10−7 M). at different time points
(6, 12, 24, and 48 h), percentage of apoptosis was deter-
mined by using FITC-labelled Annexin V and propidium
iodide (PI) (Biolegend). Briefly, 1 × 106 cells were resus-
pended in 100 μL of binding buffer (Biolegend) containing
annexin V and PI according to manufacturer’s instruc-
tions. After incubation for 15 min in the dark at room
temperature, cells were analyzed with a Beckman Counter
FC500 using FlowJo software.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 software. Data are expressed as the mean ± SEM.
The statistical significance of differences was evaluatedby Student’s t-test. Values of P < 0.05 were considered to
be significant.Results
Kinetics of cell surface PD-1 expression during T cell
activation
PD-1 is an inducible costimulatory molecule expressed
on T cells, B cells, natural killer (NK) cells, dendritic
cells (DCs) and monocytes upon activation [15–17]. Pre-
vious study has examined that PD-1 is not expressed on
resting T cells but is inducibly expressed within 24 h
after stimulation [18]. As an initial step to understand
the basis for the effect of DEX on PD-1, we first analyzed
the dynamic changes of PD-1 expression on activated T
cells. Freshly isolated mouse splenocytes without stimula-
tion were analyzed by flow cytometry. Data showed there
is almost no expression on resting CD3-positive T cells
(Fig. 1 Day 0). Then cells were stimulated with anti-CD3/
CD28 beads at 1:1 bead-to-cell ratio for 1-7d. As shown in
Fig. 1, both the mean fluorescence intensity (MFI) and
proportion of PD-1+ T cells were up-regulated within 24 h
and reached a peak at 48 h, followed by reduction in the
next days. It returned to background levels by day 7. On
the basis of these findings, we chose 48 h as our next
observation time point.DEX enhances PD-1 expression both in mouse and human
activated T cells
To investigate the effects of DEX on PD-1 expression in
mouse T cells after activation, DEX at different doses (10−9
to 10−5 M) were added to culture medium at the same
time with activation. Forty-eight hours later, cells were
collected for flow cytometry. Results suggest that DEX
dose-dependently enhanced the expression of PD-1 at
48 h with EC50 values of 10
−7 M (Fig. 2a). Though data
showed DEX at 10−9 M slightly reduced the expression
than control, this difference has no significance (P > 0.05)
(Fig. 2a). To further explore whether this effect exists
during whole activation, mouse T cells were incubated
with anti-CD3/CD28 beads in the absence or presence
of 1 × 10−7 M DEX from day 1 to day 7. We found DEX
enhanced PD-1 expression at each time point, with differ-
ence more significantly from day 2 to day 4 (p < 0.05)
(Fig. 2b). These results confirmed our hypothesis that
DEX could enhance PD-1 expression during T cell activa-
tion. We also observed that surface expression of PD-1
was upregulated in both CD4+ and CD8+ T cells (Fig. 2c).
Besides, our results revealed that DEX did not induce PD-1
expression in unstimulated T cells (data not shown).
To ascertain whether DEX exerts similar effect on hu-
man T cells, we treated activated human T cells with DEX
(10−7 M). The flow cytometry experiments demonstrated
that following 48 h treatment, DEX also increases surface
Fig. 1 (See legend on next page.)
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Fig. 1 Kinetics of surface PD-1 expression of T lymphocytes during activation. Cells were double-stained with Percp-cy5.5 labeled anti-CD3 antibody
and either PE-labeled isotype control or anti-PD-1 antibody. a Dynamic variation of MFI of PD-1 expression on mouse CD3+ T cells after activation.
b Dynamic variation of ratio of PD-1 expression on mouse CD3+ T cells after activation. c Representative flow cytometry histograms of PD-1 expression
(red) and isotype control (cyan) gated on CD3+ T cells from day 1 to day 7 after activated (day 0 represent the baseline). d Representative dot plots
showing the percentage of T cells expressing PD-1 from day 1 to day 7 after activated (day 0 represent the baseline). Data shown are representative
of three independent experiments
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cells (Fig. 2d).
Effect of DEX on PD-1 mRNA and protein level
To determine whether DEX affected PD-1 expression
at the mRNA level, mouse T cells were stimulated for
2 days with or without DEX (10−7 M). As shown in
Fig. 2e, quantitative RT-PCR determined that PD-1
mRNA was increased significantly by DEX. The mean
augmentation of PD-1 mRNA by DEX-treated group
was determined to be more than fourfold over that of
DEX-untreated group.Fig. 2 Effects of DEX on PD-1 expression on activated T cells. a Mouse T ce
or presence of various doses of DEX (10−9-10−5 M). b Mouse T cells were incuba
DEX for 0 to 7 days. DEX significantly increased PD-1 expression. c DEX increase
increased PD-1 expression in both CD4+ and CD8+ subsets of human T c
cells by real-time PCR analysis. Data are presented as the mean fold chan
blot analyses confirming higher expression of PD-1 protein in DEX-treated T celWestern blot analysis showed that addition of DEX to
activated T cells resulted in a significant increase of PD-
1 protein (Fig. 2f ). These data showed that DEX-induced
augmentation of PD-1 expression by flow cytometry
analysis correlates with an augmentation of both PD-1
mRNA and PD-1 protein.
RU486 overcomes DEX-induced upregulation of PD-1
expression
GCs mediate their well-defined transcriptional effects via
a cytoplasmic glucocorticoid receptor (GR) which belongs
to the nuclear receptor superfamily. In the cytoplasm,lls were incubated with anti-CD3/CD28 beads for 48 h in the absence
ted with anti-CD3/CD28 beads in the absence or presence of 1 × 10−7 M
d PD-1 expression in both CD4+ and CD8+ subsets of mouse T cells. d DEX
ells. e Analysis of PD-1 mRNA level in DEX-treated and untreated T
ge in PD-1 mRNA level normalized to the β-actin mRNA. f Western
ls. Data represents mean ± SEM of three experiments. *p < 0.05. **p < 0.01
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the activated receptor and subsequent binding to negative
or positive GR responsive elements (GREs) in the promoter
regions of target genes [19]. RU486 has been described as a
GR antagonist and was used to block activities of GCs
mediated through GR.
In order to determine if the DEX-induced increase in
PD-1 expression is due to specific glucocorticoid-GR
interaction, the ability of RU486 to block the hormone
effect was studied. Splenocytes were stimulated in the
presence of DEX (1 × 10−7 M) alone or DEX plus various
doses RU486 (1 × 10−9–10−5 M). The results showed that
the augmentation of PD-1 expression by DEX was dose-
dependently inhibited by RU486 (Fig. 3), indicating that
the effect of DEX on PD-1 is mediated through the GR.
Different T cell subsets show different sensitivity to DEX-
induced upregulation of PD-1 expression
T cells can be divided into several different subsets accord-
ing to their functional and phenotypic features. According
to the expression of the differentiation markers CD44 and
CD62L, T cells can be divided into three subsets. A naïve
phenotype (naïve T cells, Tn) is characterized by expression
of low levels of CD44 and high levels of CD62L (CD44loFig. 3 RU486 inhibits DEX-mediated increase of PD-1 expression.
a Cells were cultured for 48 h in (a) medium (b) with 1 × 10−7 M
DEX or (c) 1 × 10−7 M DEX plus 1 × 10−5 M RU486 for 48 h. Cells
were stained with isotype control (cyan histograms) or PE-labeled
anti-PD-1 antibody (red histograms). b Cells were cultured for 48 h
with 1 × 10−7 M DEX or 1 × 10−7 M DEX plus different doses of RU486
or 1 × 10−7 M RU486 alone. Data is presented as the mean ± SEM of
three experiments. *p < 0.05. **p < 0.01CD62Lhi). When naïve T cells react to antigen during the
immune response, a small proportion of the responding
cells survives to form antigen-specific memory T cells
(Tm); these cells are typically CD44hi, with some of the cells
being CD62Lhi (central memory T cells, Tcm) and others
being CD62Llo (effector memory T cells, Tem) [20]. Flow
cytometry results showed that the expression of PD-1 had a
significant difference between them, with Tem expressing
the highest level and Tn the lowest (Fig. 4). Interestingly,
these three subsets we gated are differentially modulated by
DEX in terms of PD-1 expression. DEX induced a strong
upregulation of PD-1 on Tcm and Tem, but a weaker
upregulation on Tn (Fig. 4).Effect of hydrocortisone (HC) on PD-1 expression in mouse
T cells
In order to assess whether less potent GCs have the same
effect, we treated activated mouse T cells with hydrocorti-
sone (HC) for 48 h. Similar to DEX, results showed that
HC also increases surface PD-1 expression in a dose-
dependent manner and this effect was inhibited by RU486
(Fig. 5a). Since HC is less potent than DEX, we noted that
only at high dose with a concentration of 10−5 M can HC
induce this effect significantly. Lower concentrations of
HC caused weak effect of this kind. Thus we concluded
that the effect of GCs on PD-1 expression depends on
their potency and dose. At the same dose, more potent
GCs such as prednisone and DEX could exert greater
effect than less potent GCs like cortisol. Besides, we
observed that the effect of HC on different subsets in
terms of PD-1 were all in line with DEX (Fig. 5b, c).Effects of DEX on the function and apoptosis of activated
T cells
GCs are potent anti-inflammatory and immunosuppressive
agents. Their immunosuppressive effects have been as-
cribed to their modulation of gene transcription, whereby
they inhibit the production of a number of cytokines
(CKs), such as interleukin-2 (IL-2), interferon-γ (IFN-γ),
and tumor necrosis factor-α (TNF-α) [21]. In vitro studies
have also shown that the engagement of PD-1 by PD-L1
or PD-L2 inhibited TCR-mediated T cell proliferation
and cytokine production including IL-2, IFN-γ and
TNF-α [17, 22].
To validate the effect of DEX on the function of activated
T cells, culture supernatants of mouse T cells activated for
48 h with DEX (10−7 M) or not were assayed for the pro-
duction of cytokines IL-2, IFN-γ, TNF-α by ELISA. Results
shown in Fig. 6a displayed significantly (p ≤ 0.01) decreased
levels of IL-2, IFN-γ and TNF-α in DEX-treated group
compared to DEX-untreated group, suggest that DEX
suppressed the production of cytokines and inhibited
the function of activated T cells.
Fig. 4 Different T cell subsets differ in their expression of PD-1 and sensitivity to DEX. Cells were incubated with anti-CD3/CD28 beads for 48 h in
the absence or presence of 1 × 10−7 M DEX. a Based on the expression of CD44 and CD62L, four subsets were gated: CD44−CD62L+ (naïve T cells, Tn),
CD44+CD62L+ (central memory T cells, Tcm), CD44+CD62L− (effector memory T cells, Tem) and CD44−CD62L− (double negative T cells). b Representative
flow cytometry histograms show PD-1expression differs in Tn, Tcm and Tem, with Tem expressing the highest level and Tn the lowest. c Tcm, Tem are
more susceptible to DEX-induced upregulation of PD-1. Data is presented as mean ± SEM of three experiments. **p < 0.01
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evaluated the apoptosis at different times (6, 12, 24, 48 h)
of treatment. Results showed significant higher levels of
apoptosis in DEX-treated cells (Fig. 6b, c).
Discussion
Activation of the immune system is recognized as an im-
portant treatment strategy against cancer. However, GCs
suppress the immune system and many studies have shown
that immunosuppression can exacerbate the metastatic
process and accelerate tumor growth [23, 24]. The present
study was designed to examine the effects of GCs on PD-1
expression during the course of T cell activation. To ex-
plore the possible effects, we first address the biological
features of PD-1. Using flow cytometry analysis, we dem-
onstrated that surface expression of PD-1 on activated T
cells peaked on day 2 and returned to background levels
after 6 days. This dynamic expression was in agreement
with previous studies [15, 16].
Next we used DEX as a model glucocorticoid. Our data
demonstrate for the first time that DEX could enhance the
expression of PD-1 during activation of T cells. This finding
is of great importance for the widespread use of DEX in
anti-cancer therapy as well as the crucial role of PD-1 intumor immunity. As an immune checkpoint, PD-1 serve to
suppress the activity of T cells and dampen the immune re-
sponse. Tumors can exploit this checkpoint and facilitate
tumor progression. This significance sheds light on the de-
velopment of monoclonal antibody targeting PD-1 against
many cancers. Two antibodies that block PD-1, pembroli-
zumab (Keytruda) and nivolumab (OPDIVO), have been
approved to treat advanced or inoperable melanoma and
the clinical responses are encouraging [25, 26]. Therefore,
the upregulation of PD-1 induced by DEX very likely pro-
tects cancer cells from being detected and eradicated by
immune system, resulting in faster tumor growth and poor
prognosis in anti-cancer therapy. We also validated that
DEX could suppress T cell functions via inhibition of cyto-
kines production such as IL-2, IFN-γ, TNF-α and induction
of apoptosis of T cells. In this respect, administration of
DEX to cancer patients may do harm to cancer patients.
Besides, we found that both DEX and HC enhances
PD-1 expression in a dose-dependent manner, indicating
that the dose of GCs administered to patients is of great
importance. Widely used in high doses in the therapy of
leukemia and lymphomas, GCs are highly suspicious to
impair the effect of chemotherapy in the clinical setting
of such cancers. For example, in the R-CHOP regimen
Fig. 5 Effects of HC on PD-1 expression in mouse T cells. a Activated
mouse T cells were cultured in medium, HC (10−9, 10−7, 10−5 M) or
HC (10−5 M) plus RU486 (10−5 M) for 48 h. Surface PD-1 expression
was increased in a dose-dependent manner and this effect was inhibited
by RU486. b PD-1 expression was increased in a dose-dependent
manner both in CD4+ and CD8+ T cells. c Tem are more susceptible to
HC-induced upregulation of PD-1. Data is presented as mean ± SEM of
three experiments. **p < 0.01
Fig. 6 Effects of DEX on the function and apoptosis of activated T
cells. Activated mouse T cells were cultured with DEX (10−7 M) or
medium for 48 h. a Culture supernatants were collected and assayed
for IL-2, TNF-α and IFR-γ. Data are shown as the mean values (±SEM)
for triplicate cultures for each experiment. The results are from two
independent experiments. Statistically significant differences between
medium alone and DEX-treated groups was evaluated at *p < 0.05
or **p < 0.01. b Following 48 h incubation, cells were analyzed for
apoptosis by FITC-Annexin V and PI staining by flow cytometric
analysis. Annexin-V-, PI- cells were live cells, Annexin-V+, PI- cells
were early apoptotic cells, Annexin-V+, PI+ cells were late apoptotic
and dead cells were PI positive. c The percentages of apoptotic cells
were labeled as Annexin V+ cells. Data is presented as mean ± SEM of
three experiments. **p < 0.01
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activity of NK cells and T cells as well as the specific anti-
tumor immune response triggered by rituximab, thus
unfavorable to the protective immunity. In this way we
suggest that alternative drugs should be applied instead
of GCs or use low dose of GCs in anti-cancer therapy. We
should minimize our application of glucocorticoids, espe-
cially high dose of glucocorticoids. Our data also showed
the effects induced by DEX were completely inhibited
by RU486, indicating that the effect of DEX on PD-1 is
mediated through GR. A better understanding of the
mechanism elucidating these effects is needed and will
require further research into the downstream signals.It should be noted that memory T cells were the sub-
population more susceptible to DEX-induced upregula-
tion of PD-1. The higher sensitivity on memory T cells
detected in this study may result in their faster apoptosis
via PD-1, which helps explain why treatment with DEX
could induce a significant decrease of memory T cells
accompanied by a relative increase of naïve T cells (data
not shown). In fact, memory T cells have more powerful
potent to recognize tumor antigens and to exert immune
response against cancers than naïve T cells. In this sense,
Xing et al. BMC Immunology  (2015) 16:39 Page 9 of 9the selective effect on memory T cells of DEX further
validate its immunosuppressive role.
Conclusion
Our findings provide evidence that dexamethasone could
suppress immune response by enhancing PD-1 which may
result in faster tumor growth and poor prognosis in the
clinical setting of anti-cancer therapy. We strongly suggest
that GCs have negative influence on anti-cancer ther-
apy despite their benefits for patients. It is necessary to
minimize our application of glucocorticoids, especially
high dose of glucocorticoids in anti-cancer therapy. Further
studies on the dual role of GCs are needed.
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